Robertson Stephens Wealth Management LLC Increases Stake in Bristol Myers Squibb Company $BMY

Key Points

• Robertson Stephens Wealth Management LLC raised its Bristol Myers Squibb stake by 296.2% in Q4, buying 32,059 shares to own 42,881 shares valued at about $2.313 million.
• EVP David V. Elkins sold 30,000 shares on April 1 at an average $61.67 (≈$1.85M), cutting his personal holding by about 15.85%.
• BMS posted a Q1 beat (EPS $1.58 vs. $1.42; revenue $11.49B) and reiterated FY guidance while highlighting growth drugs and pipeline catalysts, but faces limited upside near the consensus $61.31 target and long‑term risk from the Eliquis patent cliff; the stock yields ~4.3%.

Robertson Stephens Wealth Management LLC boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 296.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,881 shares of the biopharmaceutical company's stock after buying an additional 32,059 shares during the quarter. Robertson Stephens Wealth Management LLC's holdings in Bristol Myers Squibb were worth $2,313,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Novem Group raised its holdings in Bristol Myers Squibb by 2.9% during the 4th quarter. Novem Group now owns 6,402 shares of the biopharmaceutical company's stock valued at $345,000 after buying an additional 183 shares during the last quarter. Dominguez Wealth Management Solutions Inc. raised its holdings in Bristol Myers Squibb by 0.8% during the 4th quarter. Dominguez Wealth Management Solutions Inc. now owns 22,404 shares of the biopharmaceutical company's stock valued at $1,208,000 after buying an additional 185 shares during the last quarter. McLean Asset Management Corp raised its holdings in Bristol Myers Squibb by 3.1% during the 4th quarter. McLean Asset Management Corp now owns 6,465 shares of the biopharmaceutical company's stock valued at $369,000 after buying an additional 192 shares during the last quarter. Bath Savings Trust Co raised its holdings in Bristol Myers Squibb by 2.3% during the 4th quarter. Bath Savings Trust Co now owns 8,743 shares of the biopharmaceutical company's stock valued at $472,000 after buying an additional 198 shares during the last quarter. Finally, Traub Capital Management LLC raised its holdings in Bristol Myers Squibb by 2.0% during the 4th quarter. Traub Capital Management LLC now owns 10,228 shares of the biopharmaceutical company's stock valued at $552,000 after buying an additional 200 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.05% of the company's stock.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY posted a Q1 beat — $1.58 EPS vs. consensus ~$1.42 and $11.49B revenue — driven by growth drugs and Eliquis outperformance, which supports near‑term cash flow. Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales
• Positive Sentiment: Management reiterated FY outlook and emphasized the “growth portfolio” (Breyanzi, Camzyos) and cost‑cutting progress as drivers of durable margin improvement. Bristol-Myers Squibb Signals Confident Path After Q1 Call
• Positive Sentiment: Pipeline catalysts could lift long‑term growth: Phase III readouts for milvexian (potential Eliquis successor) and Cobenfy (schizophrenia) are highlighted as multi‑year drivers. BMS brings the buzz around late-stage readouts amid a so-so Q1
• Neutral Sentiment: Analysts’ consensus price target sits near $61.31, indicating limited upside from current levels absent new positive catalysts. Bristol Myers Squibb Company NYSE: BMY Receives $61.31 Consensus PT from Analysts
• Negative Sentiment: FY 2026 guidance (EPS 6.05–6.35; revenue $46.0–47.5B) left the revenue midpoint slightly below the Street, tempering upside after the quarter and contributing to profit‑taking. Bristol Myers Squibb Reports First Quarter Financial Results for 2026
• Negative Sentiment: Analysts/coverage notes emphasize the scale of the Eliquis patent cliff (multi‑billion dollar risk over coming years), which pressures valuation beyond near‑term beats. Thinning revenues: inside the $14bn Eliquis patent cliff
• Negative Sentiment: Bernstein maintained a Hold rating, signaling that some investors and analysts want clearer evidence that growth and pipeline will offset legacy declines. Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

Analyst Ratings Changes

Several research analysts have commented on the stock. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a "sector perform" rating and a $60.00 price objective for the company. Barclays assumed coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They issued an "overweight" rating and a $75.00 price objective for the company. Guggenheim restated a "buy" rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Cantor Fitzgerald upped their price objective on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a "neutral" rating in a report on Wednesday, April 8th. Finally, Morgan Stanley restated an "underweight" rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $61.31.

Bristol Myers Squibb Stock Down 3.9%

Shares of Bristol Myers Squibb stock opened at $58.24 on Friday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The company has a 50-day moving average of $59.56 and a 200 day moving average of $54.55. The firm has a market cap of $118.92 billion, a price-to-earnings ratio of 16.36, a PEG ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 66.57%. Bristol Myers Squibb's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.29 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.